| HOME >> BIOLOGY >> TECHNOLOGY |
TEL AVIV, Israel, June 17 /PRNewswire-FirstCall/ -- BSP Ltd., (http://www.bsp.co.il/pressall.asp) an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease, announced that they successfully raised $2.6 million in a private funding round, that included existing shareholders in the company as well as new investors.
BSP developed the HyperQ(TM), a cutting-edge technology that offers highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic Heart Disease - the No. 1 killer in the world.
Thousands of patients in Israel, Europe and the US have already been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD. The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking.
The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient and outpatient hospital settings, private doctor offices and major research centers.
Further applications on the company's scope; include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; and the implementation of the HyperQ(TM) technology in implantable cardiac devices.
"The completion of this round reflects our investors' ongoing confidence in our ability to meet our commercial and clinical milestones. This round will enable us to step-up the marketing and business development efforts in the US, and accelerate development of BSP's next application - the HyperQ bedside monitor," said Dr. Amir Beker, CEO of BSP.
Dr. Beker added, "The HyperQ(TM) technology is a revolutionary
non-invasive so
'/>"/>
| SOURCE BSP - Biological Signal Processing Ltd Copyright©2008 PR Newswire. All rights reserved |